View Item 

Show simple item record

2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis

dc.contributor.authorOnel, Karen B.
dc.contributor.authorHorton, Daniel B.
dc.contributor.authorLovell, Daniel J.
dc.contributor.authorShenoi, Susan
dc.contributor.authorCuello, Carlos A.
dc.contributor.authorAngeles-Han, Sheila T.
dc.contributor.authorBecker, Mara L.
dc.contributor.authorCron, Randy Q.
dc.contributor.authorFeldman, Brian M.
dc.contributor.authorFerguson, Polly J.
dc.contributor.authorGewanter, Harry
dc.contributor.authorGuzman, Jaime
dc.contributor.authorKimura, Yukiko
dc.contributor.authorLee, Tzielan
dc.contributor.authorMurphy, Katherine
dc.contributor.authorNigrovic, Peter A.
dc.contributor.authorOmbrello, Michael J.
dc.contributor.authorRabinovich, C. Egla
dc.contributor.authorTesher, Melissa
dc.contributor.authorTwilt, Marinka
dc.contributor.authorKlein-Gitelman, Marisa
dc.contributor.authorBarbar-Smiley, Fatima
dc.contributor.authorCooper, Ashley M.
dc.contributor.authorEdelheit, Barbara
dc.contributor.authorGillispie-Taylor, Miriah
dc.contributor.authorHays, Kimberly
dc.contributor.authorMannion, Melissa L.
dc.contributor.authorPeterson, Rosemary
dc.contributor.authorFlanagan, Elaine
dc.contributor.authorSaad, Nadine
dc.contributor.authorSullivan, Nancy
dc.contributor.authorSzymanski, Ann Marie
dc.contributor.authorTrachtman, Rebecca
dc.contributor.authorTurgunbaev, Marat
dc.contributor.authorVeiga, Keila
dc.contributor.authorTurner, Amy S.
dc.contributor.authorReston, James T.
dc.date.accessioned2022-04-08T18:06:57Z
dc.date.available2023-05-08 14:06:54en
dc.date.available2022-04-08T18:06:57Z
dc.date.issued2022-04
dc.identifier.citationOnel, Karen B.; Horton, Daniel B.; Lovell, Daniel J.; Shenoi, Susan; Cuello, Carlos A.; Angeles-Han, Sheila T. ; Becker, Mara L.; Cron, Randy Q.; Feldman, Brian M.; Ferguson, Polly J.; Gewanter, Harry; Guzman, Jaime; Kimura, Yukiko; Lee, Tzielan; Murphy, Katherine; Nigrovic, Peter A.; Ombrello, Michael J.; Rabinovich, C. Egla; Tesher, Melissa; Twilt, Marinka; Klein-Gitelman, Marisa ; Barbar-Smiley, Fatima ; Cooper, Ashley M.; Edelheit, Barbara; Gillispie-Taylor, Miriah ; Hays, Kimberly; Mannion, Melissa L.; Peterson, Rosemary; Flanagan, Elaine; Saad, Nadine; Sullivan, Nancy; Szymanski, Ann Marie; Trachtman, Rebecca; Turgunbaev, Marat; Veiga, Keila; Turner, Amy S.; Reston, James T. (2022). "2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis." Arthritis Care & Research 74(4): 521-537.
dc.identifier.issn2151-464X
dc.identifier.issn2151-4658
dc.identifier.urihttps://hdl.handle.net/2027.42/172074
dc.publisherWiley Periodicals, Inc.
dc.title2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelGeriatrics
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/172074/1/acr24853.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/172074/2/acr24853_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/172074/3/acr24853-sup-0001-Disclosureform.pdf
dc.identifier.doi10.1002/acr.24853
dc.identifier.sourceArthritis Care & Research
dc.identifier.citedreferenceKimura Y, Grevich S, Beukelman T, Morgan E, Nigrovic PA, Mieszkalski K, et al. Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic juvenile idiopathic arthritis consensus treatment plans. Pediatr Rheumatol Online J 2017; 15: 23.
dc.identifier.citedreferenceBuckley L, Ware E, Kreher G, Wiater L, Mehta J, Burnham JM. Outcome monitoring and clinical decision support in polyarticular juvenile idiopathic arthritis. J Rheumatol 2020; 47: 273 – 81.
dc.identifier.citedreferenceRahimi H, Twilt M, Herlin T, Spiegel L, Pedersen TK, Kuseler A, et al. Orofacial symptoms and oral health‐related quality of life in juvenile idiopathic arthritis: a two‐year prospective observational study. Pediatr Rheumatol Online J 2018; 16: 47.
dc.identifier.citedreferenceFrid P, Nordal E, Bovis F, Giancane G, Larheim TA, Rygg M, et al. Temporomandibular joint involvement in association with quality of life, disability, and high disease activity in juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2017; 69: 677 – 86.
dc.identifier.citedreferenceBollhalder A, Patcas R, Eichenberger M, Muller L, Schroeder‐Kohler S, Saurenmann RK, et al. Magnetic resonance imaging followup of temporomandibular joint inflammation, deformation, and mandibular growth in juvenile idiopathic arthritis patients receiving systemic treatment. J Rheumatol 2020; 47: 909 – 16.
dc.identifier.citedreferenceStoll ML, Amin D, Powell KK, Poholek CH, Strait RH, Aban I, et al. Risk factors for intraarticular heterotopic bone formation in the temporomandibular joint in juvenile idiopathic arthritis. J Rheumatol 2018; 45: 1301 – 7.
dc.identifier.citedreferenceRingold S, Thapa M, Shaw EA, Wallace CA. Heterotopic ossification of the temporomandibular joint in juvenile idiopathic arthritis. J Rheumatol 2011; 38: 1423 – 8.
dc.identifier.citedreferenceLochbuhler N, Saurenmann RK, Muller L, Kellenberger CJ. Magnetic resonance imaging assessment of temporomandibular joint involvement and mandibular growth following corticosteroid injection in juvenile idiopathic arthritis. J Rheumatol 2015; 42: 1514 – 22.
dc.identifier.citedreferenceResnick CM, Vakilian PM, Kaban LB, Peacock ZS. Quantifying the effect of temporomandibular joint intra‐articular steroid injection on synovial enhancement in juvenile idiopathic arthritis. J Oral Maxillofac Surg 2016; 74: 2363 – 9.
dc.identifier.citedreferenceInce DO, Ince A, Moore TL. Effect of methotrexate on the temporomandibular joint and facial morphology in juvenile rheumatoid arthritis patients. Am J Orthod Dentofacial Orthop 2000; 118: 75 – 83.
dc.identifier.citedreferenceStoustrup P, Twilt M, Herlin T. Systemic treatment for temporomandibular joint arthritis in juvenile idiopathic arthritis. J Rheumatol 2020; 47: 793 – 5.
dc.identifier.citedreferenceOmbrello MJ, Arthur VL, Remmers EF, Hinks A, Tachmazidou I, Grom AA, et al. Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications. Ann Rheum Dis 2017; 76: 906 – 13.
dc.identifier.citedreferenceDe Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367: 2385 – 95.
dc.identifier.citedreferenceRuperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367: 2396 – 406.
dc.identifier.citedreferencePascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin‐1 (IL‐1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL‐1 blockade. J Exp Med 2005; 201: 1479 – 86.
dc.identifier.citedreferenceRavelli A, Minoia F, Davi S, Horne A, Bovis F, Pistorio A, et al. 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation collaborative initiative. Arthritis Rheumatol 2016; 68: 566 – 76.
dc.identifier.citedreferenceMinoia F, Davì S, Horne A, Demirkaya E, Bovis F, Li C, et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol 2014; 66: 3160 – 9.
dc.identifier.citedreferenceDeWitt EM, Kimura Y, Beukelman T, Nigrovic PA, Onel K, Prahalad S, et al. Consensus treatment plans for new‐onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2012; 64: 1001 – 10.
dc.identifier.citedreferenceVastert SJ, de Jager W, Noordman BJ, Holzinger D, Kuis W, Prakken BJ, et al. Effectiveness of first‐line treatment with recombinant interleukin‐1 receptor antagonist in steroid‐naive patients with new‐onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol 2014; 66: 1034 – 43.
dc.identifier.citedreferenceSchulert GS, Yasin S, Carey B, Chalk C, Do T, Schapiro AH, et al. Systemic juvenile idiopathic arthritis–associated lung disease: characterization and risk factors. Arthritis Rheumatol 2019; 71: 1943 – 54.
dc.identifier.citedreferenceBsila RS, Inglis AE, Ranawat CS. Joint replacement surgery in patients under thirty. J Bone Joint Surg Am 1976; 58: 1098 – 104.
dc.identifier.citedreferenceMertelsmann‐Voss C, Lyman S, Pan TJ, Goodman SM, Figgie MP, Mandl LA. US trends in rates of arthroplasty for inflammatory arthritis including rheumatoid arthritis, juvenile idiopathic arthritis, and spondyloarthritis. Arthritis Rheumatol 2014; 66: 1432 – 9.
dc.identifier.citedreferenceSura A, Failing C, Sturza J, Stannard J, Riebschleger M. Patient characteristics associated with response to NSAID monotherapy in children with systemic juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2018; 16: 2.
dc.identifier.citedreferenceWoo P, Southwood TR, Prieur AM, Doré CJ, Grainger J, David J, et al. Randomized, placebo‐controlled, crossover trial of low‐dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 2000; 43: 1849 – 57.
dc.identifier.citedreferenceTer Haar NM, van Dijkhuizen EHP, Swart JF, van Royen‐Kerkhof A, El Idrissi A, Leek AP, et al. Treatment to target using recombinant interleukin‐1 receptor antagonist as first‐line monotherapy in new‐onset systemic juvenile idiopathic arthritis: results from a five‐year follow‐up study. Arthritis Rheumatol 2019; 71: 1163 – 73.
dc.identifier.citedreferenceLehman TJ, Schechter SJ, Sundel RP, Oliveira SK, Huttenlocher A, Onel KB. Thalidomide for severe systemic onset juvenile rheumatoid arthritis: a multicenter study. J Pediatr 2004; 145: 856 – 7.
dc.identifier.citedreferenceRuperto N, Quartier P, Wulffraat N, Woo P, Ravelli A, Mouy R, et al. A phase II, multicenter, open‐label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum 2012; 64: 557 – 67.
dc.identifier.citedreferenceLovell DJ, Giannini EH, Reiff AO, Kimura Y, Li S, Hashkes PJ, et al. Long‐term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum 2013; 65: 2486 – 96.
dc.identifier.citedreferenceQuartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicentre, randomised, double‐blind, placebo‐controlled trial with the interleukin‐1 receptor antagonist anakinra in patients with systemic‐onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011; 70: 747 – 54.
dc.identifier.citedreferenceOtten MH, Prince FH, Anink J, Ten Cate R, Hoppenreijs EP, Armbrust W, et al. Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register. Ann Rheum Dis 2013; 72: 721 – 7.
dc.identifier.citedreferenceDavies SV, Dean JD, Wardrop CA, Jones JH. Epstein‐Barr virus‐associated haemophagocytic syndrome in a patient with juvenile chronic arthritis. Br J Rheumatol 1994; 33: 495 – 7.
dc.identifier.citedreferenceMcPeake JR, Hirst WJ, Brind AM, Williams R. Hepatitis A causing a second episode of virus‐associated haemophagocytic lymphohistiocytosis in a patient with Still’s disease. J Med Virol 1993; 39: 173 – 5.
dc.identifier.citedreferenceAytac S, Batu ED, Unal S, Bilginer Y, Cetin M, Tuncer M, et al. Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus. Rheumatol Int 2016; 36: 1421 – 9.
dc.identifier.citedreferenceEloseily EM, Weiser P, Crayne CB, Haines H, Mannion ML, Stoll ML, et al. Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis. Arthritis Rheumatol 2020; 72: 326 – 34.
dc.identifier.citedreferenceOhmura SI, Uehara K, Yamabe T, Tamechika S, Maeda S, Naniwa T. Successful use of short‐term add‐on tocilizumab for refractory adult‐onset still’s disease with macrophage activation syndrome despite treatment with high‐dose glucocorticoids, cyclosporine, and etoposide. Mod Rheumatol Case Rep 2020; 4: 202 – 7.
dc.identifier.citedreferenceSonmez HE, Demir S, Bilginer Y, Ozen S. Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature. Clin Rheumatol 2018; 37: 3329 – 35.
dc.identifier.citedreferenceShenoi S, Nanda K, Schulert GS, Bohnsack JF, Cooper AM, Edghill B, et al. Physician practices for withdrawal of medications in inactive systemic juvenile arthritis, Childhood Arthritis and Rheumatology Research Alliance (CARRA) survey. Pediatr Rheumatol Online J 2019; 17: 48.
dc.identifier.citedreferenceQuartier P, Alexeeva E, Tamas C, Chasnyk V, Wulffraat N, Palmblad K, et al. Tapering canakinumab monotherapy in patients with systemic juvenile idiopathic arthritis in clinical remission: results from an open‐label, randomized phase IIIb/IV study. Arthritis Rheumatol 2020; 73: 336 – 46.
dc.identifier.citedreferenceRice JB, White AG, Scarpati LM, Wan G, Nelson WW. Long‐term systemic corticosteroid exposure: a systematic literature review. Clin Ther 2017; 39: 2216 – 29.
dc.identifier.citedreferenceZak M, Pedersen FK. Juvenile chronic arthritis into adulthood: a long‐term follow‐up study. Rheumatology (Oxford) 2000; 39: 198 – 204.
dc.identifier.citedreferenceOen K, Malleson PN, Cabral DA, Rosenberg AM, Petty RE, Cheang M. Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol 2002; 29: 1989 – 99.
dc.identifier.citedreferenceYokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic‐onset juvenile idiopathic arthritis: a randomised, double‐blind, placebo‐controlled, withdrawal phase III trial. Lancet 2008; 371: 998 – 1006.
dc.identifier.citedreferenceAl‐Matar MJ, Petty RE, Tucker LB, Malleson PN, Schroeder ML, Cabral DA. The early pattern of joint involvement predicts disease progression in children with oligoarticular (pauciarticular) juvenile rheumatoid arthritis. Arthritis Rheum 2002; 46: 2708 – 15.
dc.identifier.citedreferenceUS Food and Drug Administration. Current and resolved drug shortages and discontinuations reported to FDA: triamcinolone hexacetonide. URL: https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Triamcinolone%20Hexacetonide%20Injectable%20Suspension%20(Aristospan)&st=c.
dc.identifier.citedreferenceLipstein EA, Muething KA, Dodds CM, Britto MT. “ I’m the one taking it”: adolescent participation in chronic disease treatment decisions. J Adolesc Health 2013; 53: 253 – 9.
dc.identifier.citedreferenceLipstein EA, Lovell DJ, Denson LA, Kim SC, Spencer C, Britto MT. Parents’ information needs and influential factors when making decisions about TNF‐α inhibitors. Pediatr Rheumatol Online J 2016; 14: 53.
dc.identifier.citedreferenceFoster HE, Marshall N, Myers A, Dunkley P, Griffiths ID. Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum 2003; 48: 767 – 75.
dc.identifier.citedreferenceGomez‐Ramirez O, Gibbon M, Berard R, Jurencak R, Green J, Tucker L, et al. A recurring rollercoaster ride: a qualitative study of the emotional experiences of parents of children with juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2016; 14: 13.
dc.identifier.citedreferenceBrunner HI, Schanberg LE, Kimura Y, Dennos A, Co DO, Colbert RA, et al. New medications are needed for children with juvenile idiopathic arthritis. Arthritis Rheumatol 2020; 72: 1945 – 51.
dc.identifier.citedreferenceGlerup M, Rypdal V, Arnstad ED, Ekelund M, Peltoniemi S, Aalto K, et al. Long‐term outcomes in juvenile idiopathic arthritis: eighteen years of follow‐up in the population‐based Nordic Juvenile Idiopathic Arthritis Cohort. Arthritis Care Res (Hoboken) 2020; 72: 507 – 16.
dc.identifier.citedreferenceGuzman J, Oen K, Huber AM, Duffy KW, Boire G, Shiff N, et al. The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh‐Out cohort. Ann Rheum Dis 2016; 75: 1092 – 8.
dc.identifier.citedreferenceBeukelman T, Patkar NM, Saag KG, Tolleson‐Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011; 63: 465 – 82.
dc.identifier.citedreferenceSaper VE, Chen G, Deutsch GH, Guillerman RP, Birgmeier J, Jagadeesh K, et al. Emergent high fatality lung disease in systemic juvenile arthritis. Ann Rheum Dis 2019; 78: 1722 – 31.
dc.identifier.citedreferenceRingold S, Weiss PF, Beukelman T, DeWitt EM, Ilowite NT, Kimura Y, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum 2013; 65: 2499 – 512.
dc.identifier.citedreferenceRingold S, Angeles‐Han ST, Beukelman T, Lovell D, Cuello CA, Becker ML, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non‐systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Rheumatol 2019; 71: 846 – 63.
dc.identifier.citedreferenceAngeles‐Han ST, Ringold S, Beukelman T, Lovell D, Cuello CA, Becker ML, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis–associated uveitis. Arthritis Rheumatol 2019; 71: 864 – 77.
dc.identifier.citedreferenceOnel KB, Shenoi S. 2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis (JIA): therapeutic approaches for oligoarthritis, temporomandibular joint arthritis (TMJ), and systemic JIA, medication monitoring, immunizations and non‐pharmacologic therapies. Presented at ACR Convergence; 2020 November 3–10; Atlanta, Georgia.
dc.identifier.citedreferenceAndrews JC, Schunemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, et al. GRADE guidelines. 15. Going from evidence to recommendation—determinants of a recommendation’s direction and strength. J Clin Epidemiol 2013; 66: 726 – 35.
dc.identifier.citedreferenceGuyatt GH, Oxman AD, Vist GE, Kunz R, Falck‐Ytter Y, Alonso‐Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924 – 6.
dc.identifier.citedreferenceBrouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ 2010; 182: E839 – 42.
dc.identifier.citedreferenceOnel KB, Horton DB, Lovell DJ, Shenoi S, Cuello CA, Angeles‐Han ST, et al. 2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis: recommendations for nonpharmacologic therapies, medication monitoring, immunizations, and imaging. Arthritis Rheumatol 2022. doi: https://onlinelibrary.wiley.com/doi/10.1002/art.42036. E‐pub ahead of print.
dc.identifier.citedreferencePetty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1998; 25: 1991 – 4.
dc.identifier.citedreferenceChhabra A, Oen K, Huber AM, Shiff NJ, Boire G, Benseler SM, et al. Real‐world effectiveness of common treatment strategies for juvenile idiopathic arthritis: results from a Canadian cohort. Arthritis Care Res (Hoboken) 2020; 72: 897 – 906.
dc.identifier.citedreferenceBrik R, Gepstein V, Berkovitz D. Low‐dose methotrexate treatment for oligoarticular juvenile idiopathic arthritis nonresponsive to intra‐articular corticosteroids. Clin Rheumatol 2005; 24: 612 – 4.
dc.identifier.citedreferenceKvien TK, Hoyeraal HM, Sandstad B. Naproxen and acetylsalicylic acid in the treatment of pauciarticular and polyarticular juvenile rheumatoid arthritis: assessment of tolerance and efficacy in a single‐centre 24‐week double‐blind parallel study. Scand J Rheumatol 1984; 13: 342 – 50.
dc.identifier.citedreferenceSato JD, Fernandes TA, Nascimento CB, Corrente JE, Saad‐Magalhaes C. Probability of remission of juvenile idiopathic arthritis following treatment with steroid joint injection. Clin Exp Rheumatol 2014; 32: 291 – 6.
dc.identifier.citedreferenceMarti P, Molinari L, Bolt IB, Seger R, Saurenmann RK. Factors influencing the efficacy of intra‐articular steroid injections in patients with juvenile idiopathic arthritis. Eur J Pediatr 2008; 167: 425 – 30.
dc.identifier.citedreferenceBreit W, Frosch M, Meyer U, Heinecke A, Ganser G. A subgroup‐specific evaluation of the efficacy of intraarticular triamcinolone hexacetonide in juvenile chronic arthritis. J Rheumatol 2000; 27: 2696 – 702.
dc.identifier.citedreferenceZulian F, Martini G, Gobber D, Agosto C, Gigante C, Zacchello F. Comparison of intra‐articular triamcinolone hexacetonide and triamcinolone acetonide in oligoarticular juvenile idiopathic arthritis. Rheumatology (Oxford) 2003; 42: 1254 – 9.
dc.identifier.citedreferenceZulian F, Martini G, Gobber D, Plebani M, Zacchello F, Manners P. Triamcinolone acetonide and hexacetonide intra‐articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double‐blind trial. Rheumatology (Oxford) 2004; 43: 1288 – 91.
dc.identifier.citedreferenceEberhard BA, Sison MC, Gottlieb BS, Ilowite NT. Comparison of the intraarticular effectiveness of triamcinolone hexacetonide and triamcinolone acetonide in treatment of juvenile rheumatoid arthritis. J Rheumatol 2004; 31: 2507 – 12.
dc.identifier.citedreferenceGuzman J, Kerr T, Ward LM, Ma J, Oen K, Rosenberg AM, et al. Growth and weight gain in children with juvenile idiopathic arthritis: results from the ReACCh‐Out cohort. Pediatr Rheumatol Online J 2017; 15: 68.
dc.identifier.citedreferenceSadeghi PA, Yahya A, Ziaee V, Moayeri H. Adrenal insufficiency in children with juvenile idiopathic arthritis (JIA) treated with prednisolone. J Compr Ped 2019; 10: e64681.
dc.identifier.citedreferenceRavelli A, Davi S, Bracciolini G, Pistorio A, Consolaro A, van Dijkhuizen EH, et al. Intra‐articular corticosteroids versus intra‐articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open‐label trial. Lancet 2017; 389: 909 – 16.
dc.identifier.citedreferenceAlbarouni M, Becker I, Horneff G. Predictors of response to methotrexate in juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2014; 12: 35.
dc.identifier.citedreferenceBava C, Mongelli F, Pistorio A, Bertamino M, Bracciolini G, Dalpra S, et al. A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease‐modifying antirheumatic therapy in juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2019; 17: 50.
dc.identifier.citedreferenceFranova J, Fingerhutova S, Kobrova K, Srp R, Nemcova D, Hoza J, et al. Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration. Pediatr Rheumatol Online J 2016; 14: 36.
dc.identifier.citedreferenceImundo LF, Jacobs JC. Sulfasalazine therapy for juvenile rheumatoid arthritis. J Rheumatol 1996; 23: 360 – 6.
dc.identifier.citedreferenceFoeldvari I, Wierk A. Effectiveness of leflunomide in patients with juvenile idiopathic arthritis in clinical practice. J Rheumatol 2010; 37: 1763 – 7.
dc.identifier.citedreferenceHaapasaari J, Kautiainen H, Isomaki H, Hakala M. Hydroxychloroquine does not decrease serum methotrexate concentrations in children with juvenile idiopathic arthritis [letter]. Arthritis Rheum 2005; 52: 1621 – 2.
dc.identifier.citedreferenceAlexeeva E, Dvoryakovskaya T, Denisova R, Sleptsova T, Isaeva K, Chomahidze A, et al. Comparative analysis of the etanercept efficacy in children with juvenile idiopathic arthritis under the age of 4 years and children of older age groups using the propensity score matching method. Mod Rheumatol 2019; 29: 848 – 55.
dc.identifier.citedreferenceAnink J, Otten MH, Prince FH, Hoppenreijs EP, Wulffraat NM, Swart JF, et al. Tumour necrosis factor‐blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register. Rheumatology (Oxford) 2013; 52: 712 – 7.
dc.identifier.citedreferenceTynjala P, Vahasalo P, Tarkiainen M, Kroger L, Aalto K, Malin M, et al. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE‐JIA): a multicentre randomised open‐label clinical trial. Ann Rheum Dis 2011; 70: 1605 – 12.
dc.identifier.citedreferenceLovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al, Pediatric Rheumatology Collaborative Study Group. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000; 342: 763 – 9.
dc.identifier.citedreferenceMannion ML, Xie F, Horton DB, Ringold S, Correll CK, Dennos A, et al. Biologic switching among non‐systemic juvenile idiopathic arthritis patients: a cohort study in the Childhood Arthritis and Rheumatology Research Alliance Registry. J Rheumatol 2020; 48: 1322 – 9.
dc.identifier.citedreferenceArmaroli G, Klein A, Ganser G, Ruehlmann MJ, Dressler F, Hospach A, et al. Long‐term safety and effectiveness of etanercept in JIA: an 18‐year experience from the BiKeR registry. Arthritis Res Ther 2020; 22: 258.
dc.identifier.citedreferenceHorneff G, Klein A, Klotsche J, Minden K, Huppertz HI, Weller‐Heinemann F, et al. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab. Arthritis Res Ther 2016; 18: 272.
dc.identifier.citedreferenceMinden K, Horneff G, Niewerth M, Seipelt E, Aringer M, Aries P, et al. Time of disease‐modifying antirheumatic drug start in juvenile idiopathic arthritis and the likelihood of a drug‐free remission in young adulthood. Arthritis Care Res (Hoboken) 2019; 71: 471 – 81.
dc.identifier.citedreferenceKearsley‐Fleet L, Davies R, Lunt M, Southwood TR, Hyrich KL. Factors associated with improvement in disease activity following initiation of etanercept in children and young people with juvenile idiopathic arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Rheumatology (Oxford) 2016; 55: 840 – 7.
dc.identifier.citedreferenceIlowite N, Porras O, Reiff A, Rudge S, Punaro M, Martin A, et al. Anakinra in the treatment of polyarticular‐course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol 2009; 28: 129 – 37.
dc.identifier.citedreferenceRypdal V, Arnstad ED, Aalto K, Berntson L, Ekelund M, Fasth A, et al. Predicting unfavorable long‐term outcome in juvenile idiopathic arthritis: results from the Nordic cohort study. Arthritis Res Ther 2018; 20: 91.
dc.identifier.citedreferenceRypdal V, Guzman J, Henrey A, Loughin T, Glerup M, Arnstad ED, et al. Validation of prediction models of severe disease course and non‐achievement of remission in juvenile idiopathic arthritis: part 1—results of the Canadian model in the Nordic cohort. Arthritis Res Ther 2019; 21: 270.
dc.identifier.citedreferenceTrincianti C, Consolaro A. Outcome measures for juvenile idiopathic arthritis disease activity. Arthritis Care Res (Hoboken) 2020; 72 Suppl: 150 – 62.
dc.identifier.citedreferenceWallace CA, Huang B, Bandeira M, Ravelli A, Giannini EH. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum 2005; 52: 3554 – 62.
dc.identifier.citedreferenceWallace CA, Giannini EH, Huang B, Itert L, Ruperto N, for the Childhood Arthritis Rheumatology Research Alliance (CARRA), the Pediatric Rheumatology Collaborative Study Group (PRCSG), and the Paediatric Rheumatology International Trials Organisation (PRINTO). American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2011; 63: 929 – 36.
dc.identifier.citedreferenceConsolaro A, Ruperto N, Bazso A, Pistorio A, Magni‐Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 2009; 61: 658 – 66.
dc.identifier.citedreferenceMcErlane F, Beresford MW, Baildam EM, Chieng SE, Davidson JE, Foster HE, et al. Validity of a three‐variable Juvenile Arthritis Disease Activity Score in children with new‐onset juvenile idiopathic arthritis. Ann Rheum Dis 2013; 72: 1983 – 8.
dc.identifier.citedreferenceTibaldi J, Pistorio A, Aldera E, Puzone L, El Miedany Y, Pal P, et al. Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis. Rheumatology (Oxford) 2020; 59: 3505 – 14.
dc.identifier.citedreferenceRavelli A, Consolaro A, Horneff G, Laxer RM, Lovell DJ, Wulffraat NM, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis 2018; 77: 819 – 28.
dc.identifier.citedreferenceKlein A, Minden K, Hospach A, Foeldvari I, Weller‐Heinemann F, Trauzeddel R, et al. Treat‐to‐target study for improved outcome in polyarticular juvenile idiopathic arthritis. Ann Rheum Dis 2020; 79: 969 – 74.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
acr24853.pdf
Size:
1.356MB
Format:
PDF
View/Open
Name:
acr24853_am.pdf
Size:
2.694MB
Format:
PDF
View/Open
Name:
acr24853-sup-0001-Disclosurefo ...
Size:
1.118MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.